Billionaire Steve Cohen's 10 Large-Cap Stock Picks with Highest Upside Potential
Steve Cohen is one of the most revered names on Wall Street, running one of the biggest hedge funds.
Thermo Fisher Scientific Inc. (TMO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 2,851,579 | $1,401,637,491 | +3% | 0.48% |
| 2. | Unisphere Establishment Hani Lazkani (Ceo) | 2,060,000 | $1,012,551,800 | +6% | 8.52% |
| 3. | Viking Global Andreas Halvorsen | 1,668,025 | $819,884,328 | +111% | 2.29% |
| 4. | Farallon Capital Thomas Steyer | 881,485 | $433,276,322 | +39% | 2.47% |
| 5. | Citadel Investment Group Ken Griffin | 864,489 | $424,922,278 | +26% | 0.07% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $535.93 | 4 | $2,143.73 | 14,268 | 2024-12-09 | Filing | |
| $555.89 | 16 | $8,894.24 | 14,264 | 2024-11-07 | Filing | |
| $526.15 | 4 | $2,104.60 | 13,101 | 2023-06-26 | Filing | |
| $134.16 | 1,000 | $134,160.00 | 14,636 | 2015-12-11 | Filing | |
| $45.84 | 36 | $1,650.24 | 25,914 | 2010-08-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $462.66 | 400 | $185,064.00 | 25,051 | 2026-04-27 | Filing | |
| $499.40 | 1,607 | $802,535.80 | 20,950 | 2026-03-11 | Filing | |
| $519.74 | 264 | $137,211.36 | 123,925 | 2026-03-05 | Filing | |
| $519.13 | 516 | $267,871.08 | 124,189 | 2026-03-05 | Filing | |
| $517.83 | 106 | $54,889.98 | 124,705 | 2026-03-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 30,427,192 | $14,955,877,586 | 0.26% | |
| 2. | 24,280,816 | $11,934,749,488 | 0.29% | |
| 3. | 16,731,668 | $8,231,823,950 | 0.28% | |
| 4. | 10,863,528 | $5,339,751,925 | 0.32% | |
| 5. | 10,776,436 | $5,296,941,734 | 0.28% |
News See All
Jim Cramer’s Thoughts on 16 Stocks: Arista, Taiwan Semi, and Big Tech’s AI Spending
In this article, we will look at the stocks that Jim Cramer highlighted as he discussed Big Tech’s AI spending.
Do You Believe in The Long-Term Growth Outlook of Thermo Fisher Scientific (TMO)?
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here.
Thermo Fisher Scientific (TMO) Announces Fiscal Q1 2026 Results
Thermo Fisher Scientific Inc. (NYSE:TMO) is one of the best stem cell therapy stocks to buy. On April 23, Thermo Fisher Scientific Inc. (NYSE:TMO) announced financial results for fiscal Q1 2026.
Jim Cramer Highlighted 21 Stocks, Including Dow and Home Depot
In this article, we will look at Jim Cramer’s latest stock calls, as he suggested investors balance portfolios with hot and cold stocks.
8 Best Stem Cell Therapy Stocks to Buy
He stated that he is not surprised at the market resilience in the face of risk factors such as the war, oil prices, and inflation, looking at the behavior of the S&P 500 and the equity market more broadly...
Thermo Fisher Scientific Inc. (NYSE:TMO) Q1 2026 Earnings Call Transcript
Operator: Good morning, ladies and gentlemen, and welcome to the Thermo Fisher Scientific 2026 First Quarter Conference Call.
8 Best Large Cap Stocks to Invest In Right Now
On April 17, Reuters reported that systematic hedge funds have bought stocks at a record pace over the past five trading sessions.
Thermo Fisher Scientific (TMO) Sets Stage for Q4 Rally with Impressive Q3 Earnings and New 52-Week High
Bristol Gate Capital Partners, an investment management company, published its Q4 2025 investor letter for the “US Equity Strategy”. A copy of the letter can be downloaded here.
Jim Cramer's Hottest GLP-1 and Weight Loss Stock Picks
In an appearance on CNBC's Fast Money in January, Ray Stevens, CEO of Structure Therapeutics, discussed the unmet potential in the obesity market.
Hedge Fund Resource Center